flipquick249 Monday, 11/06/17 09:52:24 PM

Quote:

---

flipquick249 Monday, 11/06/17 09:52:24 PM


"CEO update passed on to me:


The purpose of the preferred issuance was 2-fold: it allowed us to retire $400K of debt on the books and it functions as a ‘poison pill’ to prevent a hostile takeover of the company while we have these appallingly low valuations.

We have no plans at this time to do a reverse split of the stock. A reverse split may be necessary in the future, but only if we have support for that reverse: that would be a legitimate, large financing coupled with a plan for an eventual uplisting.

The low share price is entirely caused by toxic debt converters. We are working with our partners to buy out the last of these notes in an attempt to stop the dilution and non-stop selling. Once these converters remove the selling pressure, we should see some stock appreciation. We all believe that Nutra Pharma is incredibly undervalued at this time and we truly believe that the market will stabilize to increase our value to a reasonable level in the near future.

I hope that this information is helpful.

Thank you for your interest in Nutra Pharma.

Rik

---